7 results
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors ... - Pharmacology ... of use) Common Side ... #Pharmacology # ... Summary #DM2 #diabetes
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... failure Common Side ... #Pharmacology # ... Summary #DM2 #diabetes
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
SGLT2 Inhibitors ... SGLT2 inhibitors ... drugs include side ... #Pharmacology # ... Medications #DM2
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... Stimulates Insulin, Inhibits ... with only few side ... Renal #Dosing #Pharmacology ... Management #Diabetes #DM2
Atrial Fibrillation (A-Fib) Summary

Symptoms:
• Palpitations, light-headedness, dizziness, dyspnea, exercise intolerance, chest pain, near-syncope, syncope.

Why?
Cardiac:
	• Valvular heart
waves • Irregular wide-complex ... creatinine, test for DM ... Direct thrombin inhibitor ... • Factor Xa inhibitors ... diagnosis #management #cardiology
Allopurinol Pharmacology Summary

Xanthine oxidase inhibitor blocking the formation of new uric acid
Initiate 1-2 days prior to
Allopurinol Pharmacology ... Xanthine oxidase inhibitor ... Dosing: 100 mg/m2 ... CrCl <10mL/min Side ... #Allopurinol #Pharmacology
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
, 350 mg/m2, and ... system (RAAS) inhibitor ... prophylactic RAAS inhibitor ... Cardiotoxicity #cardiology ... #oncology #pharmacology